Leukemia, Myeloid, Acute

"Leukemia, Myeloid, Acute" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.

Descriptor ID	D015470
MeSH Number(s)	C04.557.337.539.275
Concept/Terms	Leukemia, Myeloid, Acute Leukemia, Myeloid, Acute Acute Myeloid Leukemia Acute Myeloid Leukemias Leukemias, Acute Myeloid Myeloid Leukemias, Acute ANLL Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Myeloblastic, Acute Leukemia, Myelocytic, Acute Leukemia, Myelogenous, Acute Leukemia, Nonlymphoblastic, Acute Leukemia, Nonlymphocytic, Acute Myeloblastic Leukemia, Acute Acute Myeloblastic Leukemia Acute Myeloblastic Leukemias Leukemia, Acute Myeloblastic Leukemias, Acute Myeloblastic Myeloblastic Leukemias, Acute Myelocytic Leukemia, Acute Acute Myelocytic Leukemia Acute Myelocytic Leukemias Leukemia, Acute Myelocytic Leukemias, Acute Myelocytic Myelocytic Leukemias, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Nonlymphoblastic Leukemia, Acute Acute Nonlymphoblastic Leukemia Acute Nonlymphoblastic Leukemias Leukemia, Acute Nonlymphoblastic Leukemias, Acute Nonlymphoblastic Nonlymphoblastic Leukemias, Acute Nonlymphocytic Leukemia, Acute Acute Nonlymphocytic Leukemia Acute Nonlymphocytic Leukemias Leukemia, Acute Nonlymphocytic Leukemias, Acute Nonlymphocytic Nonlymphocytic Leukemias, Acute Acute Myelogenous Leukemia Acute Myelogenous Leukemias Leukemias, Acute Myelogenous Myelogenous Leukemias, Acute Myeloid Leukemia, Acute, M1 Myeloid Leukemia, Acute, M1 Leukemia, Myeloid, Acute, M1 Acute Myeloid Leukemia without Maturation Leukemia, Myeloid, Acute, M2 Leukemia, Myeloid, Acute, M2 Myeloid Leukemia, Acute, M2 Acute Myeloid Leukemia with Maturation

Below are MeSH descriptors whose meaning is more general than "Leukemia, Myeloid, Acute".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Leukemia [C04.557.337]
Leukemia, Myeloid [C04.557.337.539]
Leukemia, Myeloid, Acute [C04.557.337.539.275]

Below are MeSH descriptors whose meaning is related to "Leukemia, Myeloid, Acute".

Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myeloid, Acute".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Leukemia, Myeloid, Acute" by people in this website by year, and whether "Leukemia, Myeloid, Acute" was a major or minor topic of these publications.

Bar chart showing 245 publications over 29 distinct years, with a maximum of 22 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	2	0	2
1997	3	1	4
1998	3	0	3
1999	0	1	1
2000	1	0	1
2001	0	1	1
2002	1	0	1
2003	2	0	2
2004	2	0	2
2005	1	0	1
2007	3	0	3
2008	5	2	7
2009	3	1	4
2010	6	1	7
2011	9	0	9
2012	8	1	9
2013	8	2	10
2014	13	0	13
2015	10	3	13
2016	8	2	10
2017	18	0	18
2018	10	1	11
2019	19	0	19
2020	18	0	18
2021	22	0	22
2022	21	0	21
2023	11	0	11
2024	13	2	15
2025	7	0	7

Below are the most recent publications written about "Leukemia, Myeloid, Acute" by people in Profiles.

Zeidner JF, Sallman DA, R?cher C, Daver NG, Leung AYH, Hiwase DK, Subklewe M, Pabst T, Montesinos P, Larson RA, Wilde L, Enjeti AK, Kawashima I, Papayannidis C, O'Nions J, Johnson L, Dong M, Huang J, Bagheri T, Hacohen Kleiman G, Lee C, Vyas P. Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood. 2025 Jul 31; 146(5):590-600.

View in: PubMed
Pyzer AR, Dillon LW, Sharon E, Karrison TG, Zha Y, Fulton N, Gui G, Andrew G, Streicher H, Sweet K, Yaghmour G, Liu JJ, Jonas BA, Schimmer AD, Grant S, Zeidan AM, Hildebrandt GC, Lowrey CH, Mattison RJ, Palmisiano N, Salhotra A, Tzachanis D, Baer MR, Lin TL, Patel P, Chen H, Stadler WM, Odenike O, Larson RA, Gajewski TF, Hourigan CS, Stock W, Liu H. Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia. Blood Adv. 2025 May 13; 9(9):2144-2152.

View in: PubMed
Gooptu M, Murdock HM, Soiffer RJ. How I treat AML relapse after allogeneic HSCT. Blood. 2025 May 08; 145(19):2128-2137.

View in: PubMed
Shastri VM, Chauhan L, Gbadamosi M, Alonzo TA, Wang YC, Aplenc R, Hirsch BA, Kolb EA, Gamis AS, Meshinchi S, Lamba JK. DNA Damage Response Pharmacogenomic (DDR_PGx) Score Predicts Response to Chemotherapy Consisting of Gemtuzumab Ozogamicin in Pediatric AML: A Report from the Children's Oncology Group. Clin Cancer Res. 2025 Mar 03; 31(5):890-898.

View in: PubMed
Gyan E, Minden MD, Kubo K, Rambaldi A, Juliusson G, J?dersten M, Kelly RJ, Szerafin L, He W, Gill SC, Hill JE, Chen C, Delgado D, Hasabou N. Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 study. Cancer. 2025 Feb 15; 131(4):e35746.

View in: PubMed
Flores DN, Moerdler S, Palmisiano N, Parsons SK, Roth ME, Devine KA. Transition to Survivorship Care for Adolescents and Young Adults (AYAs) with Acute Leukemia: Provider Perspectives. J Adolesc Young Adult Oncol. 2025 Oct; 14(5):434-441.

View in: PubMed
Xu Y, Li SC, Xiao J, Liu Q, Cherukuri D, Liu Y, Mirshahidi S, Xu J, Chen X, Homa D, Olea J, Wu K, Kelly KR, Sun F, Huang R, Wang X, Wen Q, Zhang X, Ghiuzeli CM, Chong E, Abdel-Azim H, Reeves ME, Baylink DJ, Cao H, Zhong JF. Exploring treatment-driven subclonal evolution of prognostic triple biomarkers: Dual gene fusions and chimeric RNA variants in novel subtypes of acute myeloid leukemia patients with KMT2A rearrangement. Drug Resist Updat. 2025 Mar; 79:101199.

View in: PubMed
Hlavaty SI, Salcido KN, Pniewski KA, Mukha D, Ma W, Kannan T, Cassel J, Srikanth YVV, Liu Q, Kossenkov A, Salvino JM, Chen Q, Schug ZT. ACSS1-dependent acetate utilization rewires mitochondrial metabolism to support AML and melanoma tumor growth and metastasis. Cell Rep. 2024 12 24; 43(12):114988.

View in: PubMed
Badar T, Nanaa A, Atallah E, Shallis RM, Craver EC, Li Z, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, Duvall A, Burkart M, Bradshaw D, Abaza Y, Stahl M, Palmisiano N, Murthy GSG, Zeidan AM, Kota V, Patnaik MM, Litzow MR. Prognostic impact of 'multi-hit' versus 'single-hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases. Haematologica. 2024 11 01; 109(11):3533-3542.

View in: PubMed
Menssen AJ, Hudson CA, Alonzo T, Gerbing R, Pardo L, Leonti A, Cook JA, Hsu FC, Lott LL, Dai F, Fearing C, Ghirardelli K, Hylkema T, Tarlock K, Loeb KR, Kolb EA, Cooper T, Pollard J, Wells DA, Loken MR, Aplenc R, Meshinchi S, Brodersen LE. CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children's Oncology Group. Haematologica. 2024 Oct 01; 109(10):3182-3193.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement